NanoViricides Inc. (NNVC)

[Ubertino]

Could do with some updating of this:

The Company has now developed additional novel drug candidates against Ebola that it believes could lead to a successful therapeutic. A nanoviricide® drug is made up of two components that are chemically connected together: a virus-binding ligand that mimics the native receptor on the host cell to which the virus binds, and a backbone polymer that makes the nanoviricide “look like” the host cell surface to the virus. There have been significant developments in the elucidation of the important cell surface receptors and attachment factors of Ebola virus recently. With this new structure based information, the Company has been able to redesign its anti-Ebola ligands.

“We believe the new anti-Ebola ligands should make the new drug candidates substantially superior to our older ones, based on the molecular modeling studies we have conducted using the structural information of interaction of Ebola virus glycoprotein with its cellular receptor Niemann-Pick C1 protein,” said Anil R. Diwan, PhD, President of the Company, “We believe that Ebola virus will not be able to avoid our drug candidates in spite of mutations, because we are mimicking NPC1, the receptor to which the virus must bind in order to infect the host cell. Of course, we must await results from actual cell culture and animal testing to further develop these candidates.”

The Company is in negotiations with several parties regarding testing the new nanoviricide drug candidates against Ebola in the required high safety environments, i.e. BSL-4 facilities.

http://ih.advfn.com/p.php?pid=nmona&article=63523830